BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CT-P51 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CT-P51\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06939595-2443@assetmemo.bio
DTSTAMP:20261121T005609Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:CT-P51: Phase 3 readout est. (NCT06939595)
DESCRIPTION:CT-P51\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Prev
 iously Untreated Metastatic Lung Cancer\nEstimated primary completion: Feb
 ruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ct-p51#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069395
 95
URL:https://assetmemo.bio/drug/ct-p51#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
